Shots:
- Incyte has reported P-III (TRuE-PN: TRuE-PN1 & TRuE-PN2) clinical program data assessing Opzelura (BID) vs vehicle in ~180 PN pts (≥18yrs.) each for 12wks
- TRuE-PN1 showed ≥4-point WI-NRS4 improvement at 12wks. (1EP; 44.6% vs 20.6%), with itch relief by Day 7 (22.4% vs 8.0%). It also met its 2EPs, incl. higher IGA-CPG-S-TS score (15.8% vs 3.9%) & treatment success (11.9% vs. 2.9%), with more pts achieving improved WI-NRS4 score by Wk. 4
- Additionally, TRuE-PN2 showed favorable trend across all 2EPs, particularly IGA-CPG-S-TS at Wk. 12 & WI-NRS4 (1EP) at Day 7, with 1EP also favoring therapy. However, statistical significance was not reached due to high PBO response; data to be presented at future meeting
Ref: Incyte | Image: Incyte
Related News:- Incyte Partners with Genesis to Develop and Commercialize Novel Small Molecules Using Genesis’ GEMS AI Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
